Literature DB >> 2905668

Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis.

A Imperato1, G Di Chiara.   

Abstract

The effect on dopamine (DA) release of D-1 and D-2 receptor agonists and antagonists applied locally in the caudate through a trans-striatal dialysis probe was studied in freely moving rats. D-2 agonists (LY 171555 and BHT 920) reduced DA release in a concentration-dependent manner. The same local application of haloperidol abolished the effect of 10 microM LY 171555 and BHT 920. A specific D-1 agonist, the catechol benzazepine SKF 38393, reduced DA release and this effect was not modified by systemic or local administration of the D-1 antagonist, SCH 23390, nor by the D-2 antagonist, haloperidol. In contrast, the non-catechol D-1 agonist, CY 208243, failed to modify DA release. Local application of the D-1 antagonist, SCH 23390, or of the D-2 antagonist, (-)-sulpiride, stimulated DA release in a concentration-dependent manner. The D-1 agonist, CY 20843, reversed the stimulatory effect of SCH 23390 but not that of (-)-sulpiride. It is concluded that D-1 and D-2 receptors located in the caudate control DA release separately in this area.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2905668     DOI: 10.1016/0014-2999(88)90284-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

1.  Effect of pergolide on endogenous and exogenous L-DOPA metabolism in the rat striatum: a microdialysis study.

Authors:  S Dethy; M A Laute; A Luxen; J Hildebrand; S Goldman
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Burst activation of dopamine neurons produces prolonged post-burst availability of actively released dopamine.

Authors:  Sweyta Lohani; Adria K Martig; Suzanne M Underhill; Alicia DeFrancesco; Melanie J Roberts; Linda Rinaman; Susan Amara; Bita Moghaddam
Journal:  Neuropsychopharmacology       Date:  2018-05-07       Impact factor: 7.853

3.  Dopamine D-2 receptor agonist-induced behavioural depression: critical dependence upon postsynaptic dopamine D-1 function. A behavioural and biochemical study.

Authors:  D M Jackson; S B Ross; L G Larsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

4.  Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats.

Authors:  A Guyon; F Assouly-Besse; G Biala; A J Puech; M H Thiébot
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  The 5-HT1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum.

Authors:  G G Nomikos; L Arborelius; B B Höök; U Hacksell; T H Svensson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  In vivo regulation of extracellular dopamine in the neostriatum: influence of impulse activity and local excitatory amino acids.

Authors:  K A Keefe; M J Zigmond; E D Abercrombie
Journal:  J Neural Transm Gen Sect       Date:  1993

7.  Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity.

Authors:  J F Marshall; S J O'Dell; F B Weihmuller
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Regulation of dopamine levels in intrastriatal grafts of fetal mesencephalic cell suspension: an in vivo voltammetric approach.

Authors:  H Moukhles; C Forni; A Nieoullon; A Daszuta
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

9.  Presynaptic regulation of extracellular dopamine levels in the medial prefrontal cortex and striatum during tyrosine depletion.

Authors:  Zachary Brodnik; Manda Double; George E Jaskiw
Journal:  Psychopharmacology (Berl)       Date:  2013-02-01       Impact factor: 4.530

10.  Towards a reconceptualization of striatal interactions between glutamatergic and dopaminergic neurotransmission and their contribution to the production of movements.

Authors:  Hélène N David
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.